Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 120845 | 1.845 |
09:34 ET | 32993 | 1.86 |
09:36 ET | 15035 | 1.85 |
09:38 ET | 21335 | 1.8599 |
09:39 ET | 15035 | 1.8599 |
09:41 ET | 22293 | 1.87 |
09:43 ET | 8334 | 1.87 |
09:45 ET | 4800 | 1.87 |
09:48 ET | 15666 | 1.87 |
09:50 ET | 5383 | 1.8708 |
09:52 ET | 11961 | 1.88 |
09:54 ET | 10107 | 1.8801 |
09:56 ET | 3331 | 1.87 |
09:57 ET | 4664 | 1.865 |
09:59 ET | 744 | 1.8612 |
10:01 ET | 4535 | 1.85 |
10:03 ET | 10533 | 1.865 |
10:06 ET | 12294 | 1.86 |
10:08 ET | 9744 | 1.86 |
10:10 ET | 41919 | 1.84 |
10:12 ET | 5544 | 1.86 |
10:14 ET | 900 | 1.865 |
10:15 ET | 2147 | 1.87 |
10:17 ET | 10966 | 1.88 |
10:19 ET | 1300 | 1.875 |
10:21 ET | 13983 | 1.89 |
10:24 ET | 35358 | 1.8627 |
10:26 ET | 70936 | 1.88 |
10:28 ET | 3750 | 1.89 |
10:30 ET | 17554 | 1.88 |
10:32 ET | 7900 | 1.88 |
10:33 ET | 18000 | 1.895 |
10:35 ET | 17410 | 1.903 |
10:37 ET | 18496 | 1.89 |
10:39 ET | 15664 | 1.9 |
10:42 ET | 1700 | 1.9007 |
10:44 ET | 3545 | 1.9 |
10:46 ET | 17388 | 1.9039 |
10:48 ET | 12577 | 1.9 |
10:50 ET | 1900 | 1.905 |
10:51 ET | 9288 | 1.8869 |
10:53 ET | 300 | 1.885 |
10:55 ET | 2100 | 1.885 |
10:57 ET | 1509 | 1.8849 |
11:00 ET | 7660 | 1.885 |
11:02 ET | 12609 | 1.8982 |
11:04 ET | 4237 | 1.895 |
11:06 ET | 100 | 1.895 |
11:08 ET | 4112 | 1.89 |
11:09 ET | 1710 | 1.89 |
11:11 ET | 3300 | 1.89 |
11:13 ET | 1400 | 1.8913 |
11:15 ET | 1000 | 1.9 |
11:18 ET | 300 | 1.9 |
11:20 ET | 400 | 1.895 |
11:22 ET | 3942 | 1.895 |
11:24 ET | 500 | 1.895 |
11:26 ET | 600 | 1.89 |
11:27 ET | 600 | 1.9 |
11:29 ET | 5000 | 1.895 |
11:31 ET | 7808 | 1.895 |
11:33 ET | 200 | 1.9 |
11:36 ET | 200 | 1.9 |
11:38 ET | 300 | 1.9 |
11:40 ET | 300 | 1.895 |
11:42 ET | 1800 | 1.8999 |
11:44 ET | 940 | 1.8915 |
11:45 ET | 900 | 1.8997 |
11:47 ET | 5300 | 1.895 |
11:49 ET | 13859 | 1.8808 |
11:51 ET | 200 | 1.885 |
11:56 ET | 500 | 1.885 |
11:58 ET | 100 | 1.89 |
12:00 ET | 4100 | 1.89 |
12:02 ET | 4205 | 1.89 |
12:03 ET | 200 | 1.89 |
12:05 ET | 1100 | 1.885 |
12:07 ET | 550 | 1.885 |
12:09 ET | 200 | 1.885 |
12:12 ET | 1100 | 1.885 |
12:14 ET | 200 | 1.88 |
12:16 ET | 20399 | 1.875 |
12:18 ET | 13495 | 1.86 |
12:20 ET | 12121 | 1.8505 |
12:21 ET | 400 | 1.855 |
12:23 ET | 10650 | 1.855 |
12:25 ET | 700 | 1.86 |
12:30 ET | 2230 | 1.86 |
12:32 ET | 800 | 1.86 |
12:34 ET | 500 | 1.86 |
12:36 ET | 3928 | 1.86 |
12:38 ET | 400 | 1.855 |
12:39 ET | 4699 | 1.87 |
12:41 ET | 8397 | 1.865 |
12:43 ET | 9699 | 1.8693 |
12:45 ET | 13713 | 1.865 |
12:48 ET | 700 | 1.865 |
12:50 ET | 40182 | 1.86 |
12:52 ET | 900 | 1.86 |
12:54 ET | 3402 | 1.865 |
12:56 ET | 13779 | 1.84 |
12:57 ET | 2344 | 1.845 |
12:59 ET | 48862 | 1.82 |
01:01 ET | 102221 | 1.81 |
01:03 ET | 20715 | 1.81 |
01:06 ET | 31359 | 1.7918 |
01:08 ET | 14800 | 1.79 |
01:10 ET | 41700 | 1.79 |
01:12 ET | 9857 | 1.79 |
01:14 ET | 1400 | 1.795 |
01:15 ET | 57400 | 1.795 |
01:17 ET | 300 | 1.795 |
01:19 ET | 4000 | 1.795 |
01:21 ET | 5188 | 1.79 |
01:24 ET | 8300 | 1.785 |
01:26 ET | 2008 | 1.785 |
01:28 ET | 650 | 1.7817 |
01:30 ET | 2500 | 1.78 |
01:32 ET | 2188 | 1.785 |
01:33 ET | 4100 | 1.785 |
01:35 ET | 100 | 1.785 |
01:37 ET | 10231 | 1.78 |
01:39 ET | 1500 | 1.78 |
01:42 ET | 6934 | 1.78 |
01:44 ET | 400 | 1.79 |
01:48 ET | 13308 | 1.78 |
01:50 ET | 300 | 1.785 |
01:51 ET | 400 | 1.785 |
01:53 ET | 300 | 1.785 |
01:55 ET | 200 | 1.78 |
01:57 ET | 900 | 1.78 |
02:00 ET | 4351 | 1.785 |
02:02 ET | 1404 | 1.786 |
02:04 ET | 400 | 1.785 |
02:06 ET | 100 | 1.785 |
02:08 ET | 400 | 1.79 |
02:09 ET | 14012 | 1.795 |
02:11 ET | 400 | 1.795 |
02:13 ET | 11500 | 1.795 |
02:15 ET | 100 | 1.795 |
02:18 ET | 6100 | 1.7906 |
02:20 ET | 3650 | 1.79 |
02:22 ET | 11100 | 1.795 |
02:24 ET | 100 | 1.795 |
02:26 ET | 2454 | 1.79 |
02:27 ET | 14597 | 1.795 |
02:29 ET | 1854 | 1.791 |
02:31 ET | 1754 | 1.795 |
02:33 ET | 197 | 1.79 |
02:36 ET | 200 | 1.795 |
02:38 ET | 300 | 1.8 |
02:40 ET | 400 | 1.8 |
02:42 ET | 700 | 1.8 |
02:44 ET | 21498 | 1.805 |
02:45 ET | 2469 | 1.8 |
02:47 ET | 2762 | 1.8 |
02:49 ET | 100 | 1.805 |
02:51 ET | 7696 | 1.795 |
02:54 ET | 300 | 1.79 |
02:56 ET | 1300 | 1.7946 |
02:58 ET | 1400 | 1.795 |
03:00 ET | 3555 | 1.79 |
03:02 ET | 1456 | 1.79 |
03:03 ET | 223 | 1.7901 |
03:05 ET | 1400 | 1.795 |
03:07 ET | 1600 | 1.79 |
03:09 ET | 3446 | 1.795 |
03:12 ET | 1400 | 1.79 |
03:14 ET | 3600 | 1.79 |
03:16 ET | 3195 | 1.795 |
03:18 ET | 46712 | 1.78 |
03:20 ET | 5720 | 1.785 |
03:21 ET | 3935 | 1.78 |
03:23 ET | 2800 | 1.78 |
03:25 ET | 25519 | 1.79 |
03:27 ET | 22882 | 1.81 |
03:30 ET | 2700 | 1.8075 |
03:32 ET | 100 | 1.805 |
03:34 ET | 1000 | 1.81 |
03:36 ET | 3861 | 1.81 |
03:38 ET | 1181 | 1.805 |
03:39 ET | 200 | 1.81 |
03:41 ET | 5600 | 1.805 |
03:43 ET | 6017 | 1.8085 |
03:45 ET | 9251 | 1.805 |
03:48 ET | 6113 | 1.805 |
03:50 ET | 10500 | 1.805 |
03:52 ET | 14213 | 1.805 |
03:54 ET | 5148 | 1.805 |
03:56 ET | 169405 | 1.795 |
03:57 ET | 46135 | 1.79 |
03:59 ET | 106813 | 1.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 139.5M | 9.1x | --- |
Spero Therapeutics Inc | 77.7M | 3.4x | --- |
2Seventy Bio Inc | 219.5M | -1.0x | --- |
Rigel Pharmaceuticals Inc | 163.4M | -8.2x | --- |
Alimera Sciences Inc | 163.5M | -2.0x | --- |
G1 Therapeutics Inc | 177.8M | -5.5x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $139.5M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.15 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 9.1x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | 7.5x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.